Lexicon Pharma (LXRX) Misses Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
Revenue Growth %: -78.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.34), $0.04 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $11.11 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
